Reda Girgis, MD
Pulmonary Disease · Grand Rapids, MINPI 1336193648
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,400 of the $60,700 with a category attached, or 64.9%. 15 manufacturers reported payments, led by Boehringer Ingelheim at 51.0% of the total. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $731.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$31K
- Genentech USA, Inc.$16K
- Merck$12K
- Actelion Pharmaceuticals US, Inc.$482
- United Therapeutics Corporation$372
- Insmed, Inc.$181
- plus $505 from 9 others
Across 124 payments — averaging $3480.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$251K
- Sanofi US Services Inc.$161K
- Pfizer$20K
What the payments were for
- Consulting fees$10,24017%
- Speaking & faculty fees$39,40065%
- Travel & lodging$8,14113%
- Food & beverage$2,8985%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 29 | $30,980 |
| Genentech USA, Inc. | 12 | $16,018 |
| Merck | 14 | $12,163 |
| Actelion Pharmaceuticals US, Inc. | 6 | $482 |
| United Therapeutics Corporation | 7 | $372 |
| Insmed, Inc. | 5 | $181 |
| Inari Medical, Inc. | 1 | $134 |
| La Jolla Pharmaceutical Company | 1 | $127 |
| Pulmonx Corporation | 1 | $126 |
| Sanofi | 2 | $40 |
| Sandoz | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $15 |
| Bayer | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Esbriet$15,866
- OFEV$10,317
- WINREVAIR$1,495
- UPTRAVI$256
- OPSUMIT$256
- FLOWTRIEVER CATHETER, S$134
- CT THROMBECTOMY SYSTEM KIT$134
- GIAPREZA$127
- Pulmonx Endobronchial Valve EBV$126
- Arikayce$116
How this compares
$60,700 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 50 | $1,227,483 |
| UptraviSelexipag | 39 | $844,956 |
| OpsumitMacitentan | 56 | $712,775 |
| Ambrisentan | 105 | $533,447 |
| AdempasRiociguat | 33 | $465,301 |
| WinrevairSotatercept-Csrk | 13 | $189,000 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $131,730 |
| Sildenafil Citrate | 92 | $58,069 |
| Tadalafil | 53 | $45,615 |
| Everolimus | 11 | $21,129 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,006 |
| Metoprolol Succinate | 46 | $1,040 |
| Acyclovir | 41 | $943 |
| Azithromycin | 32 | $624 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $482 | $1,557,73095 claims |
| BayerAdempas | $13 | $465,30133 claims |
| MerckWinrevair | $12,163 | $189,00013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Grand Rapids
- Gustavo Cumbo NacheliGrand Rapids$724K
- Sherry KuoGrand Rapids$30K
- Ashley ScottGrand Rapids$30K
- Anupam KumarGrand Rapids$29K
- Maria Katrina AbrilGrand Rapids$21K
- Paul HarrisGrand Rapids$20K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.